Phase 1 Gene Therapy Trial In Patients With Advanced Heart Failure Using A Novel Cardiotropic AAV Vector Targeting Protein Phosphatase Inhibitor-1

被引：0

作者：

Henry, Timothy D., II ^{[1
]}

Chung, Eugene ^{[1
]}

Alvisi, Monica ^{[2
]}

Sethna, Ferzin ^{[3
]}

Murray, David E. ^{[4
]}

Traverse, Jay H. ^{[5
]}

Chen, Youjun ^{[3
]}

Webb, Stacy ^{[3
]}

Mittal, Monika ^{[3
]}

Ervin, Leigh ^{[6
]}

Walker, Kaitlyn ^{[6
]}

Sadek, Hesham A. ^{[7
]}

Mikhail, Sheila ^{[8
]}

Haghighi, Kobra ^{[9
]}

Jiang, Canwen ^{[8
]}

Samulski, Richard J. ^{[8
]}

Kranias, Evangelia L. ^{[10
]}

Tretiakova, Anna ^{[11
]}

Hajjar, Roger J. ^{[12
]}

机构：

[1] Christ Hosp, Cardiol, Cincinnati, OH 45219 USA

[2] ASKBIO, CHF, Berlin, Germany

[3] ASKBIO, Rsch & Dev, Rsch Triangle Pk, NC USA

[4] Univ Wisconsin, Cardiol, Madison, WI USA

[5] Allina Hlth Minneapolis Heart Inst, Cardiol, Minneapolis, MN USA

[6] ASKBIO, Clin Operat, Rsch Triangle Pk, NC USA

[7] Hesham Sadek, Cardiol, Irving, TX USA

[8] ASKBIO, Rsch Triangle Pk, NC USA

[9] Univ Cincinnati, Cardiol, Cincinnati, OH USA

[10] Univ Cincinnati, Coll Med, Pharmacol, Cincinnati, OH 45221 USA

[11] ASKBIO, Rsch, Rsch Triangle Pk, NC USA

[12] Massachusetts Gen Brigham, Gene & Cell Therapy Inst, Cambridge, MA USA

来源：

CIRCULATION | 2023年 / 148卷 / 25期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

23484

引用

页码：E301 / E302

页数：2

共 50 条

[21] Ongoing phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors; Interim results
Wang, J.
Nemunaitis, J.
Chiorean, G.
Lorusso, P.
Courtney, K.
Olguin, A.
Bullington, J.
Shemesh, S.
Chen, J.
Brooks, C.
Bauer, T. M.
ANNALS OF ONCOLOGY, 2017, 28
[22] The phase II clinical trial of targeting therapy using 131I-hepama-1 in patients with HCC
Chen, S. L.
Li, B. L.
Xie, H.
Xu, L.
Nu, G. J.
Fan, S.
Fan, Q. X.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S324 - S325
[23] Sustained Improvement in Clinical Outcomes with MYDICAR® Compared to Optimal Therapy 1-year after Initial Gene Therapy in Patients with Advanced Heart Failure-The CUPID Trial
Mancini, Donna
CIRCULATION, 2010, 122 (21)
[24] CARDIAC-TARGETED AAV-S100A1 HEART FAILURE GENE THERAPY: TRANSLATION OF A NOVEL MOLECULAR TARGET TOWARDS CLINICAL CARE
Pleger, Sven T.
Kszienyk, Jan
Bekeredjian, Raffi
Qiu, Gang
Weber, Christophe
Katus, Hugo
Koch, Walter J.
Mueller, Oliver
Most, Patrick
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E236 - E236
[25] Interim results from a phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors.
Wang, Judy Sing-Zan
Barve, Minal A.
Chiorean, E. Gabriela
LoRusso, Patricia
Courtney, Kevin Dale
Qi, Dan
Olguin, Arturo
Bullington, John
Sardone, Megan
Dunn, Vanessa
Shemesh, Shay
Chen, Janice
Brooks, Christopher
Bauer, Todd Michael
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[26] Considerable Regional Variation in AAV1 Neutralizing Antibodies and Its Consequences for a Multinational Clinical Trial of Gene Transfer for Advanced Heart Failure: The CUPID 2 Experience
Greenberg, Barry
Butler, Javed
Felker, Michael G.
Voors, Adriaan
Guerrero, Jan L.
Pogoda, Janice M.
Provost, Roger
Wagner, Kim
Ponikowski, Piotr
JOURNAL OF CARDIAC FAILURE, 2014, 20 (08) : S93 - S93
[27] Evaluation of the Long-Term Effects of AAV1/SERCA2a Gene Therapy on Clinical Events in Heart Failure Patients Using a Novel Statistical Model: Results and Implications for Future Trials
Greenberg, Barry
Yaroshinsky, Alex
Dittrich, Howard
Rudy, Jeff
Zsebo, Krisztina
JOURNAL OF CARDIAC FAILURE, 2012, 18 (08) : S59 - S59
[28] Admission Levels of C-Reactive Protein and Plasminogen Activator Inhibitor-1 in Patients With Acute Myocardial Infarction With and Without Cardiogenic Shock or Heart Failure on Admission
Akkus, Mehmet Necdet
Polat, Gurbuz
Yurtdas, Mustafa
Akcay, Burak
Ercetin, Neslihan
Cicek, Dilek
Doven, Oben
Sucu, Nehir
INTERNATIONAL HEART JOURNAL, 2009, 50 (01) : 33 - 45
[29] Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial
Hulot, Jean-Sebastien
Salem, Joe-Elie
Redheuil, Alban
Collet, Jean-Philippe
Varnous, Shaida
Jourdain, Patrick
Logeart, Damien
Gandjbakhch, Estelle
Bernard, Claude
Hatem, Stephane N.
Isnard, Richard
Cluzel, Philippe
Le Feuvre, Claude
Leprince, Pascal
Hammoudi, Nadjib
Lemoine, Francois M.
Klatzmann, David
Vicaut, Eric
Komajda, Michel
Montalescot, Gilles
Lompre, Anne-Marie
Hajjar, Roger J.
EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (11) : 1534 - 1541
[30] Phase 1 trial of SNS-314, a novel selective inhibitor of aurora kinases A, B, and C, in advanced solid tumor patients
Robert, F.
Hurwitz, H.
Verschraegen, C. F.
Advani, R.
Berman, C.
Taverna, P.
Evanchik, M.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 5 →